Evidence map›Paper›PMID 37586318›Full record

ArticleCell reports. Medicine2023

A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8

Yao-Wen Chang, Huey-Wen Hsiao, Ju-Pei Chen, Sheue-Fen Tzeng, Chin-Hsien Tsai, Chun-Yi Wu, Hsin-Hua Hsieh, Santiago J Carmona, Massimo Andreatta, Giusy Di Conza and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Liver-directed AAV-IL-10 therapy enhances CD8Journal for immunotherapy of cancer · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Orchestration of Tumor-Associated Macrophages in the Tumor Cell-Macrophage-CD8International journal of biological sciences · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Yao-Wen ChangCancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
Huey-Wen HsiaoElixiron Immunotherapeutics (Hong Kong) Ltd., Hong Kong.
Ju-Pei ChenCancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
Sheue-Fen TzengGraduate Institute of Life Sciences, National Defense Medical Center, Taipei 11221, Taiwan.
Chin-Hsien TsaiGraduate Institute of Life Sciences, National Defense Medical Center, Taipei 11221, Taiwan.
Chun-Yi WuDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
Hsin-Hua HsiehDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
Santiago J CarmonaDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research at University of Lausanne, Lausanne, Switzerland.
Massimo AndreattaDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research at University of Lausanne, Lausanne, Switzerland.
Giusy Di ConzaDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research at University of Lausanne, Lausanne, Switzerland.
Mei-Tzu SuDepartment of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
Pandelakis A KoniElixiron Immunotherapeutics (Hong Kong) Ltd., Hong Kong.
Ping-Chih HoDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research at University of Lausanne, Lausanne, Switzerland.
Hung-Kai ChenElixiron Immunotherapeutics (Hong Kong) Ltd., Hong Kong. Electronic address: hkchen@elixiron.com.
Muh-Hwa YangCancer and Immunology Research Center, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan; Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan; Department of Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Department of Teaching and Research, Taipei City Hospital, Taipei, Taiwan. Electronic address: mhyang2@nycu.edu.tw.
National Yang Ming Chiao Tung University · TWLudwig Cancer Research · CHNational Defense Medical Center · TWElixiron Immunotherapeutics (Taiwan) · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Strategies to increase intratumoral concentrations of an anticancer agent are desirable to optimize its therapeutic potential when said agent is efficacious primarily within a tumor but also have significant systemic side effects. Here, we generate a bifunctional protein by fusing interleukin-10 (IL-10) to a colony-stimulating factor-1 receptor (CSF-1R)-blocking antibody. The fusion protein demonstrates significant antitumor activity in multiple cancer models, especially head and neck cancer. Moreover, this bifunctional protein not only leads to the anticipated reduction in tumor-associated macrophages but also triggers proliferation, activation, and metabolic reprogramming of CD8

Indexed as

Antineoplastic AgentsNeoplasmsCD8-Positive T-LymphocytesHumansInterleukin-10Receptor Protein-Tyrosine KinasesReceptors, Colony-Stimulating FactorTumor MicroenvironmentAntineoplastic AgentsInterleukin-10Receptor Protein-Tyrosine KinasesReceptors, Colony-Stimulating FactorCD8 T cellcolony-stimulating factor 1-receptorhead and neck cancerimmunotherapyinterleukin-10macrophageTCR repertoiretumor microenvironment

Identifiers

PMID37586318
PMCPMC10439276
OpenAlexW4385841244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.